Abstract
Angioplasty of the coronary arteries has made significant headway in the past 20 years as a treatment for atherosclerotic vascular disease. Though drug-eluting stents are effective, they appear to invoke a thrombogenic response. Biodegradable stents are a promising alternative to permanent stents and may eventually be used to solve the lingering problem of in-stent restenosis. Additionally, fully degradable stents have the ability to deliver more drugs to the target site than a thin coating of drug on metallic stents. A variety of degradable materials have been studied for stent design, including polyesters, polycarbonates, bacterial-derived polymers, and corrodible metals. The ideal biodegradable stent would be reliably deployable under fluoroscopic guidance and situate into the target lesion with minimal endovascular trauma. The stent should degrade into nontoxic byproducts and invoke a minimal degree of inflammation at the target site. Finally, the stent itself should disappear within months (to years) without significant displacement from the deployment site. Although initial data from clinical trials have been sufficient to bring biodegradable materials into the realm of feasibility, future research is undoubtedly necessary to resolve the critical issues of inflammation and mechanical stability.
Keywords: Restenosis, stent, drug, bioabsorption, biodegradation, Angioplasty, atherosclerotic vascular disease, polyesters, polycarbonate, femoral artery., Intravascular ultrasound, in-stent restenosis, brachytherapy, sirolimus, tacrolimus, everolimus, zotarolimus, mycophenolic acid, thrombosis, antiplatelet therapy, poly-L-lactic acid, polyglycolic acid, poly-anhydrides, minimal lumen diameter, ST638, tyrosine kinase inhibitor, neointimal hyperplasia, optical coherence tomography, endothelialization, salicylic acid, poly-anhydride ester, salicylic-acid polymer, magnetic resonance imaging, anti-ferromagnetism
Current Pharmaceutical Design
Title: Biodegradable and Bioabsorbable Stents
Volume: 16 Issue: 36
Author(s): Ron Waksman and Rajbabu Pakala
Affiliation:
Keywords: Restenosis, stent, drug, bioabsorption, biodegradation, Angioplasty, atherosclerotic vascular disease, polyesters, polycarbonate, femoral artery., Intravascular ultrasound, in-stent restenosis, brachytherapy, sirolimus, tacrolimus, everolimus, zotarolimus, mycophenolic acid, thrombosis, antiplatelet therapy, poly-L-lactic acid, polyglycolic acid, poly-anhydrides, minimal lumen diameter, ST638, tyrosine kinase inhibitor, neointimal hyperplasia, optical coherence tomography, endothelialization, salicylic acid, poly-anhydride ester, salicylic-acid polymer, magnetic resonance imaging, anti-ferromagnetism
Abstract: Angioplasty of the coronary arteries has made significant headway in the past 20 years as a treatment for atherosclerotic vascular disease. Though drug-eluting stents are effective, they appear to invoke a thrombogenic response. Biodegradable stents are a promising alternative to permanent stents and may eventually be used to solve the lingering problem of in-stent restenosis. Additionally, fully degradable stents have the ability to deliver more drugs to the target site than a thin coating of drug on metallic stents. A variety of degradable materials have been studied for stent design, including polyesters, polycarbonates, bacterial-derived polymers, and corrodible metals. The ideal biodegradable stent would be reliably deployable under fluoroscopic guidance and situate into the target lesion with minimal endovascular trauma. The stent should degrade into nontoxic byproducts and invoke a minimal degree of inflammation at the target site. Finally, the stent itself should disappear within months (to years) without significant displacement from the deployment site. Although initial data from clinical trials have been sufficient to bring biodegradable materials into the realm of feasibility, future research is undoubtedly necessary to resolve the critical issues of inflammation and mechanical stability.
Export Options
About this article
Cite this article as:
Waksman Ron and Pakala Rajbabu, Biodegradable and Bioabsorbable Stents, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454905
DOI https://dx.doi.org/10.2174/138161210794454905 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Suppression of Premature Stop Mutations that Cause Genetic Diseases
Current Pharmacogenomics Identification of Canonical Transient Receptor Potential (TRPC) Channel Proteins in Native Vascular Smooth Muscle Cells
Current Medicinal Chemistry The Classic Basic Protein of Myelin – Conserved Structural Motifs and the Dynamic Molecular Barcode Involved in Membrane Adhesion and Protein-Protein Interactions
Current Protein & Peptide Science Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway
CNS & Neurological Disorders - Drug Targets Transient Receptor Potential Channels, the Kidney and Hypertension
Current Hypertension Reviews Antioxidant Activity of Plant Phenols: Chemical Mechanisms and Biological Significance
Current Organic Chemistry Vasculogenesis and Angiogenesis Depend on the Developmental Origin in the Arterial Tree
Current Medicinal Chemistry Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Influence of Lifestyle Measures on Hypertriglyceridaemia
Current Drug Targets Molecular Mechanisms of Diabetes and Atherosclerosis: Role of Adiponectin
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Phenotype and Mutation Spectrum of Alzheimer’s Disease with Causative Genetic Mutation in a Chinese Cohort
Current Alzheimer Research Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy HDL-C Levels and Cardiovascular Disease: More is not Always Better!
Recent Patents on Cardiovascular Drug Discovery Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options
Current Vascular Pharmacology Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology